In this regard, there are multiple pharmacological compounds, including inhibitors/antagonists of DAMPs, P2X7R, IL-1β signaling, caspase-1, NF-κB, and antioxidant molecules that have demonstrated the capacity to dampen the NLRP3 inflammasome and pyroptosis in the liver, showing promising beneficial effects in the prevention of liver disease progression (Table 1). Here, NLRP3 is linked to liver disorder.